Key takeaways
- The UK FSA is recommending ministerial approval of three high-purity CBD novel foods (RP 7, RP 350, and RP 427) at up to 10 mg/day.
- Labels would carry a 10 mg adult daily limit and warnings for under-18s, pregnancy or breastfeeding, and people on medication or immunosuppressed.
- EFSA has not authorized any CBD novel food and set a much lower provisional safe intake (~2 mg/day), creating a UK–EU divergence in CBD policy.
A UK Food Standards Agency (FSA) paper has recommended authorizing three cannabidiol (CBD) novel food applications. Backed by the agency’s previous positive safety assessment and public consultation, the regulatory greenlight would advance CBD foods across Great Britain if ministers agree to the proposals.
The first three CBD novel food applications are RP 7 synthetic CBD, RP 350 CBD isolate, and RP 427 CBD isolate — ≥98% pure CBD — designed for adults with a maximum dose of 10 mg/day. The FSA shares that there are 3,000 individual CBD products linked to these three applications, indicating that its recommendations will help move the CBD market into regulatory compliance and support consumer confidence.
The public consultation revealed strong support for risk management proposals, such as clear labeling and protections for vulnerable groups. The FSA says it will assist in guiding enforcement authorities and continue to evaluate other CBD applications.
It also points out that FSA’s safety standards vary from those of the European Food Safety Authority (EFSA), which has not published positive safety assessments for CBD novel foods. EFSA concluded that safety could not be set for pregnant women, breastfeeding mothers, people taking medications, or anyone under 25 due to potential developmental and liver risks.
Ultimately, UK ministers will make the final decision on their applications based on the FSA’s safety and risk management advice.
Read the full article at
https://www.nutritioninsight.com/news/uk-fsa-cbd-novel-food-authorization.html
